WuXi AppTec to Raise $981M via Hong Kong Share Placement for Global Expansion

WuXi AppTec (SS:603259), a leading Chinese pharmaceutical services company, announced plans to raise HK$7.70 billion (US$981 million) through a Hong Kong share placement to accelerate its global expansion and boost production capacity.

The company will issue 73.8 million new H-shares priced at HK$104.27 each, representing a 6.9% discount to its July 30 closing price. The placement accounts for approximately 2.51% of WuXi AppTec’s enlarged share capital and will be allocated to at least six institutional investors, according to the company’s statement.

WuXi AppTec stated that net proceeds of around HK$7.65 billion will be used mainly to fund overseas growth, with 90% earmarked for international expansion and capacity building projects. The remaining funds will be allocated for general corporate purposes.

This capital raising comes as WuXi AppTec continues to strengthen its global footprint in contract research, development, and manufacturing services amid rising demand for pharmaceutical outsourcing. The move aligns with the company’s strategy to enhance international operations and meet growing customer needs in key markets such as the United States and Europe.

The placement underscores investor confidence in WuXi AppTec’s growth prospects despite broader market volatility. By securing substantial funding, the company is positioned to expand its global infrastructure and maintain its competitive edge in the fast-evolving life sciences sector.